Trial · NCT07908225
Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
NCT07908225, Not applicable, Active not recruiting, Peijia Medical Technology (Suzhou) Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis. Trials, record NCT07908225. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908225
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
- NCT number
- NCT07908225
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 150 participants, actual
- Lead sponsor
- Peijia Medical Technology (Suzhou) Co., Ltd.
- Conditions
- Aortic Stenosis
- Interventions
- TAVR
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | All-cause mortality at 12 months | 1 year | All-cause mortality |
| Secondary | Device Success | immediately after the procedure | Vascular access, delivery and deployment of the prosthetic aortic valve were successful, and the delivery system was successfully withdrawn. A prosthetic aortic valve was accurately implanted in the anatomical position. The prosthetic aortic valve met the expected requirements (mean transaortic pressure gradient \< 20 mmHg or transaortic flow velocity \< 3 m/s; no moderate or greater prosthetic aortic regurgitation or paravalvular leakage). |
| Secondary | Procedural Success | Perioperative/Periprocedural | device success with no occurrence of death, disabling stroke, myocardial infarction, or conversion to surgery within 72 hours post-procedure or before discharge |
| Secondary | Improvement in cardiac function (NYHA functional class) | 1 year | |
| Secondary | Postoperative quality of life of subjects (EuroQol five-dimension questionnaire [EQ-5D] visual analogue scale [VAS] score) | 1 year | The EuroQol five-dimension questionnaire (EQ-5D) visual analogue scale (VAS) score ranges from 0 to 100, with higher scores indicating a better self-rated health state. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908225
GET https://conductscience.org/api/trials/v1/NCT07908225/registered